The mechanisms of HLA-DM-catalyzed peptide exchange remain uncertain. Here we found that all stages of the interaction of HLA-DM with HLA-DR were dependent on the occupancy state of the peptide-binding groove. High-affinity peptides were protected from removal by HLA-DM through two mechanisms: peptide binding induced the dissociation of a long-lived complex of empty HLA-DR and HLA-DM, and high-affinity HLA-DR-peptide complexes bound HLA-DM only very slowly. Nonbinding covalent HLA-DR-peptide complexes were converted into efficient HLA-DM binders after truncation of an N-terminal peptide segment that emptied the P1 pocket and disrupted conserved hydrogen bonds to HLA-DR. HLA-DM thus binds only to HLA-DR conformers in which a critical part of the binding site is already vacant because of spontaneous peptide motion.
The mechanisms of HLA-DM-catalyzed peptide exchange remain uncertain. Here we found that all stages of the interaction of HLA-DM with HLA-DR were dependent on the occupancy state of the peptide-binding groove. High-affinity peptides were protected from removal by HLA-DM through two mechanisms: peptide binding induced the dissociation of a long-lived complex of empty HLA-DR and HLA-DM, and high-affinity HLA-DR-peptide complexes bound HLA-DM only very slowly. Nonbinding covalent HLA-DR-peptide complexes were converted into efficient HLA-DM binders after truncation of an N-terminal peptide segment that emptied the P1 pocket and disrupted conserved hydrogen bonds to HLA-DR. HLA-DM thus binds only to HLA-DR conformers in which a critical part of the binding site is already vacant because of spontaneous peptide motion.
Efficient surveillance of the surface of antigen-presenting cells by CD4 + T cells requires long-lived display of peptides bound to major histocompatibility complex class II (MHCII) molecules. High-affinity peptides are kinetically trapped in the peptide-binding groove and dissociate extremely slowly (within days to weeks at 37 °C) 1, 2 . Such stable binding is enabled by a conserved hydrogen-bonding network between the MHC helices and the backbone of bound peptides, as well as by occupancy of MHC pockets by peptide side chains 3, 4 .
Empty MHCII molecules quickly lose their ability to rapidly bind peptide and aggregate 5, 6 . Before the arrival of MHCII in the late endosomal peptide-loading compartment, the binding groove is protected by the CLIP (class II-associated Ii peptide) segment of the invariant chain 7 . Cleavage of the invariant chain in the late endosomal compartment leaves the CLIP peptide in the binding groove 8, 9 ; CLIP is bound with a wide range of affinities by different allelic forms of MHCII (ref. 10) . HLA-DM (human) and H2-DM (mouse) serve a critical role in antigen presentation by MHCII by accelerating the removal of CLIP and by editing the peptide content of MHCII molecules such that the display of high-affinity peptides is favored 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . HLA-DM also acts as a chaperone that maintains empty MHCII in a highly peptidereceptive state [21] [22] [23] . Mass spectrometry analysis of HLA-DM-MHCII complexes purified from antigen-presenting cells has shown them to be largely devoid of peptide 22 .
Crystal structures of MHCII, HLA-DM and H2-DM have been available for many years (since 1993 (MHCII) and 1998 (HLA-DM and H2-DM)), but it has been challenging to define the molecular mechanisms of HLA-DM-catalyzed peptide exchange 4, 24, 25 . Comprehensive mutagenesis has identified large lateral surfaces of HLA-DM and HLA-DR required for their interaction; of particular interest are HLA-DR residues in the vicinity of the N terminus of the peptide (Phe51 and Glu40 of HLA-DRα) 26, 27 . The proximity of the HLA-DM-interaction site to the N terminus of the peptide has also been demonstrated by covalent attachment of a peptide to a surfaceaccessible cysteine residue at position 46 of HLA-DMβ and subsequent loading of this HLA-DM-linked peptide into the HLA-DR1 peptidebinding groove. Such a complex is stable when HLA-DM is linked to the C terminus of the peptide, but HLA-DM catalyzes rapid peptide dissociation when linked to the N terminus of the peptide 28 .
Two main models of HLA-DM action have been proposed. The first model suggests that HLA-DM breaks some of the conserved hydrogen bonds between the peptide backbone and the MHC helices 24, 29 , whereas the second model proposes more global conformational changes 30 . The first model has been supported by functional data showing that the rate of HLA-DMinduced peptide dissociation is proportional to the intrinsic rate of peptide dissociation for all peptides and MHCII molecules tested 29 . These data suggest that bonds conserved in all peptide-MHCII interactions are targeted by HLA-DM, such as conserved hydrogen bonds formed by HLA-DRα Phe51, HLA-DRα Ser53 and HLA-DRβ His81 near the N terminus of the peptide 24 . An initial report indicated that HLA-DRβ His81 was the target of HLA-DM action 31 , but other studies have shown that substitution of this residue does not result in less susceptibility to HLA-DM 32, 33 . Furthermore, individual substitution of all MHC side chains that form conserved hydrogen bonds to the peptide backbone (nine hydrogen bonds in total) did not identify a substitution A r t i c l e s that resulted in less susceptibility to HLA-DM 32 . Finally, loss of hydrogen bonds to the main-chain atoms of HLA-DRα Phe51 and HLA-DRα Ser53 enhances susceptibility to HLA-DM rather than diminishing it, which suggests that these hydrogen bonds are not direct targets of HLA-DM 34 .
The second model of HLA-DM action proposes that HLA-DM globally distorts the MHCII binding groove rather than breaking a small number of hydrogen bonds. Analysis of a large number of HLA-DR-peptide complexes has shown that the intrinsic stability of any one complex is a poor predictor of susceptibility to HLA-DM and that interactions along the entire length of the groove affect susceptibility to HLA-DM 30 . Dynamic light-scattering and circular-dichroism studies have further indicated that HLA-DR undergoes conformational changes after peptide binding 35 .
A central problem in defining the mechanism of HLA-DM-catalyzed peptide exchange is that it remains unknown which HLA-DRpeptide conformers interact with HLA-DM. We report here that the interaction of HLA-DM with HLA-DR was highly dependent on the occupancy of the peptide-binding groove, with high-affinity peptides destabilizing empty HLA-DR-HLA-DM complexes. Furthermore, HLA-DM bound only to HLA-DR-peptide conformers in which key interactions between the N terminus of the peptide and the HLA-DR molecule had already been lost because of peptide motion.
RESULTS
Peptide destabilizes HLA-DR−HLA-DM complexes HLA-DM-catalyzed peptide exchange is a multistep process that has been difficult to study mechanistically because most assays do not isolate individual steps but instead represent a mixture of multiple rates. We developed a real-time surface plasmon resonance (SPR) assay to directly study the individual steps of the interaction of HLA-DR with HLA-DM (Fig. 1) . We oriented HLA-DM on streptavidin chips through C-terminal site-specific biotinylation so that the large lateral surface required for binding to HLA-DR was fully accessible. We generated soluble HLA-DR-CLIP complexes with a cleavable CLIP linker. In SPR experiments, it is critical to use suitable control proteins to ensure the specificity of binding; we therefore identified HLA-DM and HLA-DR mutants with loss of activity in a real-time peptidebinding assay based on fluorescence polarization (FP; Fig. 1a,c) . Substitution of one arginine residue at position 98 of HLA-DMα with alanine (R98A; called 'HLA-DM Mut1' here) resulted in less HLA-DM activity, whereas an additional substitution of the arginine residue at position 194 of HLA-DMα with alanine (R98A and R194A; called 'HLA-DM Mut2' here) resulted in loss of activity (Fig. 1a) . The SPR binding data closely correlated with those functional data, showing little binding of HLA-DR to HLA-DM Mut1 and no binding to HLA-DM Mut2 (Fig. 1b) . Also, an HLA-DR2 (DRB1*1501) mutant with substitution of the serine residue at position 53 with aspartic acid (HLA-DRα S53D) that was unresponsive to HLA-DM in the FP assay (Fig. 1c) failed to bind to HLA-DM, as assessed by SPR ( Fig. 1d and Supplementary Fig. 1 ). This mutant HLA-DR2 bound peptide with kinetics similar to those of wild-type HLA-DR2 (Fig. 1c) , which indicated correct folding.
In these SPR experiments, we injected HLA-DR-CLIP complexes over the HLA-DM surface (stage 1), followed by injection of buffer (stage 2; Fig. 1b,d) . Unexpectedly, the dissociation of HLA-DR from HLA-DM during stage 2 was very slow, even though soluble HLA-DM and HLA-DR are thought to interact only weakly 36 . We reasoned that the catalytic activity of HLA-DM removed the HLA-DR-bound CLIP, which exited with the buffer flow, whereas peptide remains available for rebinding in typical tube-based experiments. We therefore postulated that injection of peptide would destabilize the complex of HLA-DM and empty HLA-DR. Indeed, injection of a high-affinity peptide of myelin basic protein amino acids 85-99 (MBP(85-99)) induced dissociation of HLA-DR2 from HLA-DM (Fig. 1e) . A single amino-acid mutant of MBP(85-99) with very low affinity for HLA-DR2 (substitution of phenylalanine at position P4 with aspartic acid (MBP P4D)) induced minimal dissociation at the same peptide concentration (1 µM; Fig. 1e ). We obtained similar binding profiles at flow rates of 15-50 µl/min (Supplementary Fig. 2 ), which indicated that rebinding (mass transport) was negligible. Injection of an antibody to the DNP group on peptides showed that the complex of HLA-DM and HLA-DR in stage 2 did not contain bound peptide (Supplementary Fig. 3) .
The rate of peptide-induced dissociation of HLA-DM-HLA-DR (stage 3) correlated closely with the affinity of these peptides for the HLA-DR2-binding site, both for sets of CLIP mutants ( Fig. 2a-d ) and for sets of MBP(85-99) mutants (Fig. 2e,f) , regardless of which peptide anchors were replaced. Peptides with high affinity for HLA-DR2, such as CLIP P4F (CLIP with substitution of the alanine residue at position P4 with phenylalanine; Fig. 2c ) or MBP(85-99) (Fig. 2f) , induced faster dissociation of HLA-DM-HLA-DR than did peptides of lower affinity. Peptides with very low affinity, such as MBP P4D, did not induce dissociation at low concentrations (such as 1 µM; Fig. 1e ) but led to some dissociation at higher concentrations (10 µM; Fig. 2e) . 
A r t i c l e s
Slow binding to HLA-DM by high-affinity complexes The fact that peptide binding induces dissociation of HLA-DM-HLA-DR complexes suggests that the HLA-DR-bound peptide probably also has a considerable effect on the reverse process; that is, the binding of HLA-DR to HLA-DM (Fig. 3) . Initial experiments showed that HLA-DR molecules with covalently bound peptides did not bind to HLA-DM (Fig. 3) ; this was true for both HLA-DR2-CLIP and HLA-DR1 (DRB1*0101) linked to a low-affinity CLIP variant (HLA-DR1-CLIP low ), even though binding was readily detectable after linker cleavage (Fig. 3a,b) . These results could be explained either by steric hindrance caused by the linker attached to the N terminus of the HLA-DRβ chain or by a substantial affinity gain resulting from covalent peptide attachment (rebinding of peptide is probably extremely rapid). The linker is flexible and also not in the immediate proximity of the predicted HLA-DM-interaction site, which makes the latter explanation more plausible. We next examined the effect of peptide affinity on the association of HLA-DR with HLA-DM using HLA-DR molecules loaded with single peptides; we synthesized peptides with a dinitrophenol (DNP) tag for affinity isolation of homogenous HLA-DR-peptide complexes. There was strong binding of HLA-DM by the low-affinity HLA-DR2-CLIP complex, but much slower binding by the high-affinity HLA-DR2-MBP(85-99) complex (Fig. 3c,d ). We also observed this effect for HLA-DR4 preloaded either with low-affinity CLIP or high-affinity influenza hemagglutinin peptide of amino acids 306-318 (HA(306-318); Fig. 3g ). CLIP binds with high affinity to HLA-DR1 (ref. 37) , and binding of the HLA-DR1-CLIP complex to HLA-DM was also slow (Fig. 3e) . Nevertheless, there was concentration-dependent binding to HLA-DM by the high-affinity HLA-DR2-MBP(85-99) and HLA-DR1-HA(306-318) complexes (Fig. 3d,f) , which indicated that both low-affinity and high-affinity HLA-DR-peptide complexes bound to HLA-DM in this SPR assay, but with different rates. In a functional peptide-binding assay, the rate of HLA-DM-catalyzed binding of a fluorescence-labeled peptide was 8.5% when the high-affinity HLA-DR2−MBP(85-99) complex rather than the low-affinity HLA-DR2-CLIP complex was used as input protein. In the SPR assay, the rate of binding of HLA-DM by HLA-DR2-MBP(85-99) was 11.5% compared with the rate of binding by HLA-DR2-CLIP ( Supplementary Fig. 4 which demonstrated overall agreement between the SPR and peptidebinding assays. Published studies with full-length HLA-DR and HLA-DM molecules isolated from cells have reported a stronger interaction of HLA-DM with HLA-DR-CLIP than with HLA-DR-peptide complexes 21, 38 ; also, a published SPR experiment has shown stronger binding of immobilized soluble HLA-DM to detergent-solubilized full-length HLA-DR-CLIP than to HLA-DR-peptide complexes 39 . In both sets of experiments, a complex mixture of peptides was bound to these cell-derived HLA-DR-peptide complexes. In the experiments we have reported here, the differences in binding were much greater because we used purified low-affinity and high-affinity HLA-DR-peptide complexes. Comparison of the HLA-DR-CLIP binding data for these three allelic forms (HLA-DR1, HLA-DR2 and HLA-DR4) also showed large differences in the HLA-DM-binding kinetics. HLA-DR2-CLIP bound with the fastest kinetics and HLA-DR1-CLIP bound with the slowest kinetics (Fig. 3c,e,g ). We also observed large differences among these allelic forms in peptide-induced dissociation of HLA-DM-HLA-DR complexes, with complexes containing HLA-DR2 being more sensitive to peptide-induced dissociation than those containing HLA-DR1 or HLA-DR4 (Fig. 3c,e,g ).
Binding to HLA-DM requires partial peptide dissociation
The results obtained with covalently linked peptides (Fig. 3a,b) raised the questions of whether HLA-DR molecules with fully bound peptides do not bind to HLA-DM and whether partial release of the bound peptide is actually required to generate a HLA-DM-sensitive conformer. To investigate this, we generated HLA-DR1 molecules to which peptides could be covalently attached in one of the pockets so that peptide termini could be truncated without peptide loss (Fig. 4) . We covalently linked mutant hemagglutinin peptides either in the P6 pocket or the P3 site by replacement of the HLA-DRα valine at position 65 or glycine at position 58 with cysteine; both residues are located on the HLA-DRα-chain helix. We made these complexes with an HLA-DR1 molecule with a very low-affinity peptide as the input protein, and we chose redox conditions that enabled efficient formation of a disulfide bond between the peptide and the HLA-DRα-helix. We generated a large set of such complexes ( Table 1 ) that we affinitypurified with DNP affinity tags on the peptides to ensure the absence of empty HLA-DR or HLA-DR species loaded with other peptides (Supplementary Fig. 5 ). We named these peptides according to the site of covalent linkage (HA 6 and HA 3 for linkage in the P6 pocket or the P3 site, respectively) and the length of the peptide, with full-length HA spanning from the P-2 to the P11 positions (HA P -2 -P 11 ; Table 1 ). We confirmed full occupancy by monitoring the ratio of absorbance at 280 nm (HLA-DR) to that at 350 nm (DNP group on peptide). Also, we immunoprecipitated HLA-DR1 molecules with linked HA 6 P 2 -P 11 peptide by conformation-sensitive antibodies to HLA-DRα and HLA-DRβ (Supplementary Fig. 6 ).
Covalent attachment of the high-affinity HA(306-318) peptide in the P6 pocket (HA 6 ; Fig. 4a ) yielded a complex that failed to bind to HLA-DM, as assessed by SPR (Fig. 4a,d) . We then systematically truncated the full-length HA peptide (which spanned from position P-2 to position P11) from the N terminus, which resulted in loss of conserved hydrogen bonds between the peptide backbone and the HLA-DR helices. Removal of the P-2 residue (peptide HA 6 P -1 -P 11 ) Table 1 HA-P 6 and HA-P 3 cysteine peptide variants Name Sequence Change or substitution HA-P 6 Cys (cysteine residue at P6) HA 6 PKYVKQNCLKLAT HA 6 P 1 A PKAVKQNCLKLAT P1 Tyr-to-Ala substitution HA 6 P 1 G PKGVKQNCLKLAT P1 Tyr-to-Gly substitution HA 6 P -1 -P 11 KYVKQNCLKLAT P-2 truncation HA 6 P 1 -P 11 YVKQNCLKLAT P-2 and P-1 truncation HA 6 P 1me -P 11 Me-YVKQNCLKLAT P-2 and P-1 truncation; N-methylation of P1 Tyr HA 6 P 1 G me -P 11 a Me-GVKQNCLKLAT P-2 and P-1 truncation; substitution of P1 Tyr with N-methylated Gly HA 6 P 2 -P 11 a VKQNCLKLAT P-2, P-1 and P1 truncation HA 6 (N-DNP) PKYVKQNCLKLAT N-terminal DNP label HA 6 P -2 -P 6 PKYVKQNC P7, P8, P9, P10 and P11 truncation; N-terminal DNP label HA-P 3 Cys (cysteine residue at P3) HA 3 PKYVCQNTLKLAT HA 3 P 1 G PKGVCQNTLKLAT P1 Tyr-to-Gly substitution HA 3 P 1me -P 11 Me-YVCQNTLKLAT P-2 and P-1 truncation; N-methylation of P1 Tyr HA 3 P 1 G me -P 11 a Me-GVCQNTLKLAT P-2 and P-1 truncation; substitution of P1 Tyr with N-methylated Gly HA 3 P 2 -P 11 a VCQNTLKLAT P-2, P-1 and P1 truncation HA 3 P 3 -P 11 a CQNTLKLAT P-2, P-1, P1 and P2 truncation HA 6 peptides have a threonine-to-cysteine substitution at position 6, and HA 3 peptides have a lysine-to-cysteine substitution at position 3. All peptides except HA 6 (N-DNP) and HA 6 P -2 -P 6 have a DNP group attached through a C-terminal lysine. Underlining indicates P1 anchor residues.
a HLA-DR-peptide complexes that bind rapidly to HLA-DM. A r t i c l e s resulted in loss of hydrogen bonds to Phe51 and Ser53 of HLA-DRα, and further truncation of P-1 (peptide HA 6 P 1 -P 11 ) also eliminated a hydrogen bond to His81 of HLA-DRβ (Fig. 4a) . Deletion of these two N-terminal peptide residues was not sufficient for binding to HLA-DM (Fig. 4d) . However, we observed strong binding to HLA-DM after further truncation of the tyrosine at P1 (peptide HA 6 P 2 -P 11 ), a critical anchor residue for binding of HLA-DR1 (ref. 40 ; Fig. 4b-d) . In contrast, truncation of five C-terminal residues (HA 6 P -2 -P 6 ) resulted in little binding to HLA-DM; the small amount of apparent binding was possibly caused by an overall increase in protein mobility due to loss of five peptide residues (Fig. 4e) .
To determine whether the effect noted above was due solely to removal of the P1 anchor residue, we tested full-length peptides with substitution to alanine or glycine at P1. Replacement of the P1 tyrosine anchor with alanine (HA 6 P 1 A) or glycine (HA 6 P 1 G) resulted in only a small amount of binding to HLA-DM (Fig. 4f) . In contrast, substantial binding was enabled by simultaneous loss of the P1 side chain (P1 glycine) and the two N-terminal residues (P 1 G me -P 11 , where 'G me ' indicates methylation of the glycine residue at the N terminus; Fig. 4f) . Substantial binding to HLA-DM therefore requires release of both the P1 anchor and the peptide residues N-terminal to it.
Loss of the P1 anchor could enable dissociation of a longer peptide segment toward the P6 position, which could be required for binding to HLA-DM. To address this possibility, we moved the covalent attachment site from the P6 pocket to the P3 site by replacement of the glycine residue at position 58 of HLA-DRα with cysteine (Table 1) . Again, removal of positions P-2 and P-1 did not permit binding to HLA-DM (HA 3 P 1me -P 11 ; where 'P 1me ' indicates methylation of the P1 position; Fig. 5a ) but further removal of the P1 side chain (HA 3 P 1 G me -P 11 ) or the P1 residue (HA 3 P 2 -P 11 ) resulted in rapid binding of these two complexes to HLA-DM (Fig. 5a) . Notably, additional truncation of the P2 residue (HA 3 P 3 -P 11 ) seemed to slow the binding to HLA-DM (Fig. 5b) , which indicated that disengagement of the P1 anchor and two N-terminal peptide residues was sufficient for binding to HLA-DM. The asparagine at position 82 of HLA-DRβ forms bidentate hydrogen bonds to the peptide backbone at position P2, and replacement of this asparagine with alanine increases the intrinsic dissociation rate of the HA peptide >3,000-fold, which indicates that it has a dominant role in stabilizing peptides in the binding groove 32, 41 . Loss of the peptide residue at position P2 may thus result in lower activity of such an HLA-DR-peptide complex due to absence of these critical hydrogen bonds. These results show that HLA-DM binds only to HLA-DR-peptide complexes with a disengaged peptide N terminus but not to complexes in which the peptide is fully bound.
Important role for HLA-DRa Trp43 in binding to HLA-DM The tryptophan at position 43 of HLA-DRα directly interacts with the tyrosine at position P1 and is partially accessible on the lateral surface of the HLA-DRα segment consisting of positions 40-54 (Fig. 6a) , which has been proposed to be involved in binding to HLA-DM. Conservative substitution of that tryptophan with phenylalanine resulted in much lower susceptibility to HLA-DM in a peptide-binding assay (Fig. 6b) , and by SPR we observed little binding to HLA-DM by this mutant (Fig. 6c) . This substitution also accelerated spontaneous release of labeled MBP(85-99) from HLA-DR2 (Fig. 6d) , a property that would actually be expected to increase binding to HLA-DM, given the data shown above. We also directly compared a panel of four HLA-DR mutants for HLA-DM-catalyzed peptide exchange and binding to HLA-DM (Fig. 6e,f) . Three HLA-DRα mutants (W43F, S53D and S53H) had much lower activity in both assays, whereas one mutant (G49S) had enhanced activity. These data show that the binding of HLA-DR to HLA-DM as well as HLA-DM-catalyzed peptide exchange require the same HLA-DR residues and hence involve the same binding site on HLA-DR. 
A r t i c l e s
High energy barrier for binding to HLA-DM Peptide exchange in the presence or absence of HLA-DM is highly dependent on both temperature and pH (refs. 11,12,42) . HLA-DR1-CLIP low and HLA-DR2-CLIP showed a steep temperature dependence for binding to HLA-DM ( Fig. 7a and Supplementary Fig. 7 ) that is unusual for protein-protein interactions. However, binding of HLA-DM by HLA-DR1 with a covalent peptide lacking three N-terminal peptide residues (HA 6 P 2 -P 11 ) was much less temperature dependent (Fig. 7b,c) , which demonstrated that dissociation of the N terminus of the peptide represents an important component of the energy barrier. With peptides of higher affinity, this energy barrier is expected to be even larger. On the basis of the association and dissociation kinetics of the binding of the covalent HLA-DR1-HA 6 P 2 -P 11 complex to HLA-DM, we calculated a dissociation constant of 1 µM (Fig. 7d) , which is consistent with the Michaelis constant of ~0.75 µM for the enzymatic reaction executed by HLA-DM 39 . Notably, both on-rates and off-rates increased to a similar extent with temperature, and the affinity was therefore maintained over this temperature range (Supplementary Fig. 8a-c) .
HLA-DM has a sharp pH optimum in the acidic range found in late endosomes 11, 12 . As expected, the binding of HLA-DR-CLIP to HLA-DM was increased by lowering of the pH from 5.5 to 4.6 (Supplementary Fig. 9a) . However, peptide-binding experiments with HLA-DR2 molecules rendered empty by photocleavage of the bound peptide showed that peptide binding was faster at higher pH (ref . 23; Supplementary Fig. 9b ). Consistent with that result, peptide-induced dissociation of the complex was slower at a pH of 4.6 (Supplementary Fig. 9a ). HLA-DR1 with a covalent truncated peptide (HLA-DR1-HA 6 P 2 -P 11 ) showed 40% of maximal binding to HLA-DM at a pH of 7.0, whereas complexes with a full-length peptide (HLA-DR1-CLIP low and HLA-DR2-CLIP) did not bind to HLA-DM at this pH (Fig. 7e-g ). Furthermore, raising the pH during stage 2, at which empty HLA-DR dissociates from HLA-DM, had little to no effect on dissociation rates (data not shown). The pH-facilitated release of the N terminus of the peptide therefore explains in part the low pH optimum of the binding of HLA-DR-peptide to HLA-DM.
Model of interaction between HLA-DM and HLA-DR The results presented above can be integrated into a new model of DM action (Supplementary Fig. 10 ) in which HLA-DR molecules with fully engaged peptides do not interact with HLA-DM until the N-terminal part of the peptide dissociates from the HLA-DR-peptide complex because of spontaneous peptide motion. HLA-DM captures this short-lived transition state and peptide quickly departs after binding to HLA-DM. The empty HLA-DM-HLA-DR complex retains the ability to quickly bind a new peptide over extended periods of time.
If an interacting peptide has low affinity, HLA-DM may catalyze its removal (editing), whereas binding of a high-affinity peptide is more likely to induce dissociation of the HLA-DM-HLA-DR complex. The resulting high-affinity HLA-DR-peptide complex has a low likelihood of rebinding HLA-DM. This model is consistent with a large body of published work in the field, including the identification of empty HLA-DR-HLA-DM complexes in cells and the demonstration of an editing function of HLA-DM and H2-DM that drives the selection of high-affinity peptides [14] [15] [16] [17] [18] [19] [20] [21] [22] 43 .
DISCUSSION
Our results here have shown that two related mechanisms protect high-affinity peptides from rapid removal by HLA-DM: the binding of such peptides in the HLA-DR groove induces dissociation of HLA-DM, and HLA-DM only slowly rebinds to such high-affinity HLA-DR-peptide complexes. These mechanisms explain how editing by HLA-DM produces HLA-DR-peptide complexes with high intrinsic stability for long-lived display on the cell surface. Forced linkage of HLA-DM and HLA-DR through leucine zipper dimerization domains attached to HLA-DMβ and HLA-DRβ chains results in rapid dissociation of both low-affinity and high-affinity peptides (a half-time of 10 s or 2 min, respectively, for CLIP or HA(306-318) bound to HLA-DR1), which shows the importance of rapid dissociation of the HLA-DR-HLA-DM complex in keeping high-affinity peptides in the binding groove 27 .
HLA-DR molecules with full-length peptides covalently linked at position P3 or P6 did not bind to HLA-DM. However, efficient binding resulted after removal of two N-terminal residues (P-1 and P-2) and truncation of the P1 side chain that serves as the main anchor for many HLA-DR-bound peptides 40 . Removal of the peptide side chain at position P1 alone resulted in only weak binding to HLA-DM. The two peptide residues N-terminal to the P1 anchor (P-2 and P-1) form conserved hydrogen bonds to Phe51 and Ser53 of HLA-DRα and His81 of HLA-DRβ 3 ; in addition, the side chains of Phe51 and Ser53 of HLA-DRα are critical for the action of HLA-DM. These results show that HLA-DM interacts with HLA-DR molecules only when the P1 pocket is vacant and conserved N-terminal hydrogen bonds to HLA-DR are disrupted; loss of either set of interactions is not sufficient for substantial binding to HLA-DM. Consistent with those results, it has been shown that filling of the P1 pocket by substitution of the residue at HLA-DRβ position 86 (glycine to tyrosine) results in much lower susceptibility to HLA-DM 44 and that loss of hydrogen bonds between the N terminus of the peptide and Phe51 and Ser53 of HLA-DRα results in greater susceptibility to HLA-DM (six-to A r t i c l e s ninefold greater) 34 . HLA-DM thus interacts only with HLA-DR conformers in which a critical part of the binding site is already empty. The segment of HLA-DRα consisting of positions 40-54 not only forms three hydrogen bonds with the backbone of the N-terminal peptide segment (HLA-DRα positions 51 and 53) but also makes substantial hydrophobic contacts that pack against the P1 pocket 3 . Published mutagenesis studies have shown that Phe51 and Glu40 of HLA-DRα are important for susceptibility to HLA-DM 26 , and our studies here have shown that the side chains of Ser53 and Trp43 of HLA-DRα are also critical. Trp43 of HLA-DRα is of particular interest because it interacts with the P1 anchor and is also partially solvent accessible in an area that has been linked to the interaction with HLA-DM. Even a conservative substitution, from tryptophan to phenylalanine, resulted in much less binding to HLA-DM, even though this substitution resulted in a moderately higher off-rate of HLA-DR-bound peptide (a change predicted to increase binding to HLA-DM). Phe51 and Ser53 of HLA-DRα (hydrogen bonds to the peptide) and Phe54 and Ala52 of HLA-DRα (hydrophobic contacts with the P1 anchor) are located on an extended strand at the N-terminal side of the HLA-DRα-chain helix that may readily adopt a new conformation when the close interactions with the N terminus of the peptide and the P1 anchor are lost. This specific area of the HLA-DRα chain shows greater flexibility than do the HLA-DR helices, as shown by higher B-factors in crystal structures of MHCII (refs. 3,4) . Molecular-dynamic simulations of the peptide-occupied state have further shown that the segment of HLA-DRα consisting of positions 50-59 shows greater mobility than do the long helices that flank the peptide-binding groove 45 .
All proteins are in constant motion, and local motions may lead to transient loss of interactions in part of the binding groove. We propose that N-terminal truncation of HA(306-318) bound to HLA-DR1 mimics a transient conformation in which part of the peptide has temporarily left the binding site. Structurally, the hydrogen bonds formed by the amino acids at positions 51 and 53 of HLA-DRα and position 81 of HLA-DRβ are surface exposed, whereas other conserved hydrogen bonds to the peptide backbone are sheltered by the helical walls of the binding groove 24 . In the absence of HLA-DM, the most likely outcome is rebinding of this peptide segment in the groove. HLA-DM seems to have a higher affinity for fully empty HLA-DR molecules than for partially peptide-filled HLA-DR molecules, as the dissociation rate of empty HLA-DR-HLA-DM complexes (stage 2) is much lower (~12%) than that of covalent HLA-DR-peptide complexes lacking the N-terminal peptide segment. When HLA-DM senses the loss of interactions surrounding the N terminus of the peptide, its higher affinity for the empty state could shift the equilibrium from a partially peptide-filled form to a fully empty form.
The binding of HLA-DR-peptide to HLA-DM showed a temperature dependence that is highly unusual for protein interactions. The temperature dependence was less steep for truncated HLA-DRpeptide complexes, which suggests that a substantial part of the input energy for binding to HLA-DM is required for dissociation of the N-terminal peptide segment. HLA-DM can catalyze peptide exchange for a wide variety of HLA-DR-peptide complexes, but the enhancement of peptide dissociation by HLA-DM varies substantially among HLA-DR-peptide complexes. In one study, the enhancement of peptide dissociation by HLA-DM for high-affinity HLA-DR-peptide complexes ranged from 1.4-fold to 227-fold (ref. 30) . Our SPR data showed slow binding to HLA-DM by high-affinity HLA-DR-peptide complexes, which suggests that the initial binding event is a ratelimiting step. How frequently such HLA-DR-peptide complexes assume a conformation compatible with binding to HLA-DM is probably influenced by many factors, including the tightness with which the N-terminal peptide segment is bound and how the binding energy is distributed along the groove. Some high-affinity peptides may become almost resistant to the action of HLA-DM because the HLA-DM-interacting conformation is accessed only infrequently.
Finally, we observed that allelic HLA-DR variants showed differences in susceptibility to the action of HLA-DM (fast binding for HLA-DR2-CLIP; intermediate binding for HLA-DR4-CLIP; slowest binding for HLA-DR1-CLIP). These differences in on-rates were explained in part by differences in affinity for CLIP; HLA-DR1 has a high affinity for CLIP, whereas HLA-DR4 binds CLIP with very low affinity 37, 46 . However, additional factors seem to contribute, because HLA-DR4-CLIP complexes bound to HLA-DM with slower kinetics than did HLA-DR2-CLIP complexes. Also, peptideinduced dissociation of the HLA-DM-HLA-DR complex seems to be more efficient for HLA-DR2 than for HLA-DR1 or HLA-DR4. The structural mechanisms that contribute to these differences in HLA-DM-binding kinetics may be complex and will need to be carefully delineated. These results also raise the possibility that MHCII polymorphisms, including those associated with autoimmune diseases, not only change the specificity of MHCII-binding pockets but also broadly affect the peptide repertoire by modifying the kinetics of HLA-DM-catalyzed peptide editing.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
